(CercleFinance.com) – Oncodesign Precision Medicine (OPM) announces the launch of a capital increase with cancellation of preferential subscription rights for an amount of around eight million euros, with a priority deadline for shareholders.
The global offer relates to a maximum number of 9,756,097 new shares to be issued at a firm price of 0.82 euro per share. It is guaranteed for approximately 75% of the total amount by subscription commitments.
In addition, OPM announces the transfer of its existing shares from Euronext Access + Paris to Euronext Growth Paris, where they will be listed from November 23, to benefit from increased visibility and direct access to the financial markets.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
